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The Journal of Molecular Diagnostics, the official journal of the 
Association for Molecular Pathology (AMP), co-owned by the 
American Society for Investigative Pathology (ASIP) and published 
by Elsevier, Inc., seeks to publish high-quality original papers on 
scientific advances in the field of molecular diagnostics, the 
translation and validation of molecular discoveries in medicine into 
the clinical diagnostic setting, and the description and application of 
technical advances in the field of molecular diagnostic medicine. The 
editors welcome for review manuscripts that contain: novel 
discoveries with direct application to clinical diagnostics or 
clinicopathologic correlations including studies in oncology, 
infectious diseases, inherited diseases, predisposition to disease, or the 
description of polymorphisms linked to disease states or normal 
variations; the application of diagnostic methodologies in clinical 
trials; or the development of new or improved molecular methods for 
diagnostic or monitoring of disease predisposition. 
Manuscript Categories. In addition to Regular Articles, the Journal 
also publishes Reviews, Commentaries, and Special Articles 
solicited by the Editor-in-Chief, as well as AMP meeting abstracts and 
other articles of interest to the membership of AMP. Authors who 
wish to publish a Review should send their curriculum vitae along 
with an outline of the proposed article for prior approval by the 
Editor-in-Chief. Reviews should have a maximum of 5,000 words, 75 
references, and 4 tables or figures (at least one of which is 
mechanistic). The Journal also features Technical Advances, which 
are intended to report breakthroughs in methodology or analytical 
tools applied to molecular diagnostics. Submissions to this category 
should include a detailed description of the methodological design and 
discussion of how this technique improves the practice of molecular 
diagnostics. 
Review Process. The Editors perform an initial evaluation on 
all submissions to determine whether they believe the manuscript will 
achieve a sufficient priority score to warrant publication. Priority is 
determined by the Editors’ assessment of the manuscript relative to 
other papers being considered. The aim is that expeditious treatment 
will enable authors to submit their manuscript elsewhere as soon as 
possible without suffering unnecessary delays. For manuscripts 
accepted for external review, the Editor-in-Chief assigns manuscripts 
to Associate Editors according to their expertise. The Associate Editor 
will solicit reviewers (typically, two external reviews are sought). 
Authors are encouraged to identify up to five potential reviewers. 
Authors may also request that specific reviewers not be used due to 
prior collaborations, known conflicts of interest, or direct competition. 
The Editors will make every effort to respect requests that are well-
founded; however, the Editors do have the authority to utilize such a 
reviewer if it is necessary for expert peer review. It is the practice of 
the Journal to conduct a blinded peer-review process. The peer-review 
process is kept completely confidential; it is considered a violation of 
this confidentiality for authors to identify or attempt to communicate 
directly with peer reviewers or Associate Editors regarding their 
manuscript. All editorial communications should be directed through 
the Editorial Office at jmd@asip.org. The reviewer comments and 
Associate Editor’s recommendation are evaluated by the Editor-in-
Chief for disposition and transmittal to the authors. Every effort is 
made to complete the review process within 35 days of the date 
received. 
Review Decisions. Only a portion of manuscripts will be accepted for 
publication. A number of worthy manuscripts will be rejected based on 
priority. The Journal will advise authors whether the manuscript is 
accepted, acceptable with revisions, rejected but encourage 
resubmission (after major revision), or rejected. A manuscript may be 
returned to the authors without outside review if the Editors find it 
inappropriate for publication in this Journal. Appeals (rebuttals) to 
editorial decisions must be submitted within 60 days to be considered. 
Journal Scientific Integrity Policy. The Journal has developed 
principles for defining proper conduct and scientific misconduct as 
well as procedures for handling such matters. General guidelines are 
described below; detailed information can be viewed at 
http://www.journals.elsevierhealth.com/periodicals/jmdi/content/
integrity. To report suspected misconduct relating to authors, 
reviewers, or Editors, send written complaint to the Editorial Office at 
The Journal of Molecular Diagnostics, 9650 Rockville Pike, Bethesda, 
Maryland, USA 20814-3993 or jmd@asip.org. Issues relating to staff 
conduct should be directed to the ASIP Executive Officer (AMP 
Executive Officer Emeritus) at the American Society for Investigative 
Pathology, 9650 Rockville Pike, Bethesda, Maryland, USA 20814-
3993 or mesobel@asip.org.  
Author Conduct. Authorship is defined as 1) substantial contributions 
to conception and design, or acquisition of data, or analysis and 
interpretation of data; 2) drafting the manuscript or revising it critically 
for important intellectual content; and 3) final approval of the version 
to be published. Authors should meet conditions 1, 2, and 3. When 
submitting a manuscript to the Journal, the corresponding author takes 
responsibility on behalf of all authors for the authorship, authenticity, 
and integrity of the research being reported. Authors should take 
special care that manuscripts submitted to the Journal are prepared in 
accordance with the Uniform Requirements for Manuscripts Submitted 
to Biomedical Journals (see http://www.icmje.org); in particular the 
ethical considerations regarding authorship, conflicts of interest, 
redundant publication, and treatment and confidentiality of research 
subjects should be carefully adhered to. Additionally, the Journal takes 
great care to secure the confidentiality and integrity of the peer-review 
process; it is considered a violation of this confidentiality for authors to 
identify or attempt to communicate directly with peer reviewers or 
Associate Editors regarding their manuscript. All editorial 
communications should be directed through the Editorial Office at 
jmd@asip.org. The Editors will consider any deliberate ethical 
violation in either the reported research or the manuscript preparation 
and review to be actionable misconduct, the potential results of which 
may be manuscript rejection or public article retraction, reporting of 
conduct to the authors’ governing institutions, and/or the denial to 
consider any future submissions to the Journal. Willful misconduct 
does not include incidents of honest misjudgment or inadvertent error. 
Detailed information regarding possible misconduct can be found in 
the Journal Scientific Integrity Policy at http://www.journals.
elsevierhealth.com/periodicals/jmdi/content/ integrity. 
Manuscript Submission. Manuscripts should be submitted online via 
the Rapid Review system (http://www.rapidreview.com/ASIP2/
CALogon.jsp). Detailed instructions on preparing and submitting files 
can be found on the author submission website at the above URL. 
Authors having difficulty submitting files online should complete the 
online submission form on Rapid Review to receive the assigned 
manuscript number. With the manuscript number clearly noted, 
electronic files (manuscript text, figures, tables, and supplemental data) 
should be emailed to the Editorial Office at jmd@asip.org or sent on 
disk by mail to: The Journal of Molecular Diagnostics, 9650 
Rockville Pike, Bethesda, Maryland, USA 20814-3993. The cover 
letter must state any conflicts of interest (both financial and personal), 
affirm that the manuscript has not been published previously and is not 
being considered concurrently by another publication, and affirm that 
all authors and acknowledged contributors have read and approved the 
manuscript. Submissions will be ineligible for review if previously 
published in any form (print or online) other than as an abstract. This 
includes any public posting of raw manuscripts or pre-reviewed 
material. 
A non-refundable manuscript processing fee of US$50 is required with 
submission. This fee should be paid electronically at the time of 
submission. Manuscripts arising from research in developing countries 
may be eligible for waiver of the submission fee only if all authors are 
located in a qualifying country (waiver must be applied for at time of 
submission; for a list of eligible countries, see Group A and Group B 
countries at http://www.who.int/hinari/eligibility/en). Otherwise, 
manuscript submission fees will not be waived. 
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Manuscript Preparation. Manuscripts should be prepared in the style 
of the Journal and in accordance with The Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals (see 
http://www.icmje.org). The preferred file format for text is MS Word. 
Standard abbreviations can be found in the CSE Style Manual (7th ed., 
2006). All pages of the manuscript should be double-spaced and 
numbered (including references, tables and figure legends); line 
numbers should also be included to assist reviewers in making 
comments. Other formatting specifications (eg, font size and type, 
margin settings, etc) are left to the authors’ discretion, as papers 
accepted for publication will be reformatted according to the print 
specifications of the Journal. Manuscripts not prepared in accordance 
with the submission guidelines detailed below may be returned to the 
authors. Authors are encouraged to include a list of nonstandard 
abbreviations to aid reviewers; however, the Journal does not publish 
abbreviations or keywords as part of the final article. In addition, 
authors should be ready to comply with Editors’ requests for copies of 
any similar works in preparation, copies of cited manuscripts that are 
submitted or in press, and/or supporting manuscript data (eg, data not 
shown, but summarized in the manuscript) that may aid the review 
process. 
Title Page(s). The title page(s) must include a concise title accurately 
reflecting the findings of the work; full names (not initials) of all 
authors; department, institution and address where the research was 
performed; number of text pages, tables and figures; a short running 
head (40 characters or less); grant numbers and sources of support 
(including departmental or institutional funding when no extramural 
funding was received); name, address, phone, fax, and email of the 
corresponding author; and name and address of author who should 
receive reprint requests if different from corresponding author. If an 
author changes employment after the study was performed, the new 
affiliation information for that author should be included as a footnote. 
Any relationships (eg, employment, consultancies, board membership, 
stock ownership, funding, honoraria, expert testimony, patents or 
royalties, travel reimbursements, industry-supplied free reagents, etc) 
with any organization or entity having a direct financial or personal 
interest in the subject matter or materials discussed in the article should 
also be clearly stated. 
Abstract. An abstract of 220 words or less should be prepared on a 
separate page and should be intelligible to the general reader without 
reference to the text. The abstract should clearly summarize the 
background, methodology, results, and significance of the study. 
Abbreviations and citations should be avoided. 
Text. The remaining sections of the text, which should include 
Introduction, Materials and Methods, Results, Discussion, and 
Acknowledgments (in this order), need not begin on new pages. 
Commonly-abbreviated terms should be spelled out in their first 
occurrence and then may be referenced in abbreviation through the 
remainder of the manuscript. The Journal requires the use of official 
gene and protein symbols, to facilitate standardization of scientific 
communication. Consult the Human Genome Organisation Gene 
Nomenclature Committee website (http://www.genenames.org/) for 
gene names and symbols and UniProt (http://www.uniprot.org) for 
protein names and symbols.  For standard mutation nomenclature, refer 
to Ogino et al, J Mol Diagn 2007 doi:10.2353/jmoldx.2007.060081. 
For a complete list of other approved nomenclature organizations (eg, 
bacteria, viruses, mice), please contact the Editorial Office.  
For Materials and Methods, authors should describe experimental and 
statistical methods in enough detail that other researchers can replicate 
results and evaluate claims. In general, inclusion of method or reagent 
details as supplementary material is not acceptable. In addition, linking 
to protocols online is not permissible as there is no guarantee that the 
information will remain unchanged and accessible in perpetuity. The 
sequences of oligonucleotides, if not previously published, should be 
provided. Novel DNA or protein sequences should be deposited to an 
appropriate database (eg, Genbank, EMBL, SWISS-PROT), with the 
accession numbers included in the manuscript. When providing 
supplier information for materials sources, company name and location 
(city and state, or city and country) should be provided. Website 
references to company information are not permitted. All novel 
materials and the procedures to prepare them should be described in 
sufficient detail to allow their reproduction (eg, DNA constructs, 
analytical software). Materials that are approved for investigational-use 
only should be clearly indicated. Special care should be taken to assure 
that statistical methods are appropriate. A careful power analysis 
undertaken at the beginning of work can help assure the significance of 
study findings.  “Discrepant Analysis” is regarded as statistically 
biased and should not be employed for assessment of assay sensitivity 
and specificity.  Reports of assay sensitivity and specificity should 
include appropriately calculated confidence intervals.  
Publication in the Journal implies that the authors agree, upon 
reasonable request, to share any materials or data that are integral to 
the results presented in the article, including whatever would be 
necessary for a skilled investigator to verify or replicate the claims. 
This may include original software code used in the data analysis. 
Agreement o share reagents or software code does not preclude the 
authors from implementing a Data Use Agreement. Authors must 
disclose upon submission any restrictions on the availability of 
materials or information, such as for patented or dual-purpose 
materials.  
Reporting guidelines for specific study designs (eg, randomized 
controlled trials) can be found online in the Uniform Requirements 
for Manuscripts Submitted to Biomedical Journals (see 
http://www.icmje.org). Authors must affirm that the research protocol 
was approved by the appropriate institutional review boards or ethics 
committees for human (including use of human cells or tissues) or 
animal experiments and that all human subjects provided appropriate 
informed consent and/or that regulations concerning the use of animals 
in research were adhered to. If race/ethnicity is reported, authors 
should state who determined race/ethnicity, how the options were 
defined, and why race/ethnicity was important in the study. Authors 
should be prepared to provide study protocol number(s) if requested. 
Manuscripts that meet the criteria set forth by STARD (Standards for 
Reporting of Diagnostic Accuracy; http://www.stard-statement.org) 
will be annotated with a special footnote on the title page. Authors who 
wish their manuscripts to receive this designation should submit a 
completed checklist (available at http://www.stard-statement.org/
pdf_and_word_documents/Checklist.PDF) at the time of submission 
for evaluation by editorial staff at the time of acceptance. 
Authors should obtain permission from all individuals named (by full 
name) in the Acknowledgments who contributed substantially to the 
work reported (eg, data collection, analysis, or writing/editing 
assistance) but did not fulfill the authorship criteria. Likewise, authors 
should receive permission from all individuals named as sources for 
personal communication or unpublished data. Such permissions should 
be affirmed by the corresponding author in the cover letter. A list of 
individual author contributions may be placed in this section as a 
separate paragraph.  
References. References should begin on a new page, be double-spaced 
and numbered in order of citation in the text, including citations in 
tables and figure legends. Citations that first appear in tables, figures, 
or supplemental data should be numbered according to the item’s first 
call out in the text; a separate reference list should not be prepared for 
supplemental data. Complete author citation is required (use of "et al" 
is not acceptable). References should conform to the style of the 
Journal. Examples follow: 
 Journals: Cecena G, Wen F, Cardiff RD, Oshima RG: Differential 
sensitivity of mouse epithelial tissues to the polyomavirus middle T 
oncogene. Am J Pathol 2006, 168:310-320 
 Books: Fishman AP: Pulmonary Hypertension and Cor Pulmonale. 
Pulmonary Diseases and Disorders. Edited by Fishman AP. New York, 
McGraw-Hill, 1988, pp. 999-1048 
 In press: To be used only for papers accepted for publication. Cite as 
for journal with (in press) in place of volume and page numbers. 
Include digital object identifier (doi) when available for online early 
publications.  
 Submitted papers/unpublished data: Cite in text only.
Web sites: Cite in text only. See Data Supplements section below for 
proper use of web site references. Use the doi when available. Include 
the name of the institution sponsoring the web site, URL address with 
direct linkage to the referenced information, and date of last access. 
Tables. Tables should be typed double-spaced and submitted after the 
main text on separate pages, as part of the manuscript. The preferred 
file format for Tables is MS Word; figure file formats (including those 
embedded in the text) are unacceptable. Tables should be black and 
white text only and should not include figures or other non-typeset 
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images. Color or gray shading is not permitted. Emphasis may be 
represented by bold, italics, and underlining. Nucleotide sequences 
should be capitalized, not lowercase. Table footnotes should use the 
following sequential symbols: *, †, ‡, §, ¶,Œ; these may be doubled up 
if needed. All symbols and abbreviations in the table should be defined 
in the footnotes. 
Figures. Authors should give considerable care in preparing figures. 
Resolution and quality of submitted images is the responsibility of the 
author; as a routine, the Journal does not provide figure enhancement 
services. Images (such as graphs and schematics) should have a white 
background; color, black, or gray is generally unacceptable. Authors 
are encouraged to carefully consider whether bar or line graphs should 
be submitted in grayscale or color, paying special attention to the 
ability of a reader to distinguish between different data points. Figures 
may consist of multiple related panels (labeled A, B, C, etc) described 
under one figure legend. Each figure (with all of its related panels) 
should be arranged on a single page as it should appear in final 
publication. Text labels in figures should use a professional looking 
font such as Arial; Comic Sans should be avoided. Figure labels should 
appear in the upper left corner as uppercase letters; refrain from using 
sub-labels (Aa, Ab, Ai, Aii, A1, A2, etc) or titles for each panel label; 
panels should be labeled chronologically from left to right. Figure 
panels submitted on separate pages will be arranged at the publisher’s 
discretion. If figures are to be published in black and white, they 
should be submitted for review in black and white. Figures should 
be sized to fit one column (8 cm) or two columns (17 cm). Maximum 
page length is 22.5 cm. Figures deviating from these dimensions will 
be sized at the publisher’s discretion. Unwanted background material 
should be excluded, and edges should be straight.  
Preparation of Images (Ethics): Taking photographs of the same 
source under varied fields of view, light intensity, magnifications, or 
contrast conditions without disclosing that the data are not unique to 
the present study constitutes suspect scientific conduct. Further, unless 
serial sections are used, the publication of identical-appearing images 
labeled with different staining techniques in different papers raises 
legitimate questions. Finally, reuse of one’s data (ie, “self-plagiarism”) 
is a copyright violation if the authors signed over copyright to the 
publisher; the reuse of such copyrighted images is at the sole discretion 
of the publisher, with proper attribution of the original publication a 
requirement of reuse. No specific feature within an image may be 
enhanced, obscured, moved, removed, or introduced. The grouping of 
images from different parts of the same gel or blot, or from different 
gels or blots, fields, or exposures must be made explicit by the 
arrangement of the figure (eg, using dividing lines) and in the figure 
legend. Adjustments of brightness, contrast, or color balance are 
acceptable only if they are applied to the whole image, whether 
experimental or control image, and as long as they do not obscure or 
eliminate any information present in the original (Portions adapted with 
permission from the JCB). Any evidence of inappropriate manipulation 
may prompt the Editors to request an explanation and access to original 
data, which the authors must make available. Information can be found 
in the Journal Scientific Integrity Policy at http://www.journals.
elsevierhealth.com/periodicals/jmdi/content/ integrity.  
Digital Art: Digital figure files are required for submission.  The 
Journal of Molecular Diagnostics’ requirement for color images is 
RGB (Red, Green, Blue) color mode. Images submitted in RGB will 
retain the vivid reds, greens, and blues of the original digital files for 
online publication. Authors should therefore submit all figures (for 
both new and revised manuscripts) in the RGB color mode. The 
preferred file formats for digital figures are PDF, TIFF, and EPS. PPT 
is discouraged due to the potential for font and layout changes 
occurring after opening in different versions of PowerPoint. For 
detailed instructions on preparing digital art for submission or 
production, visit http://www.elsevier.com/wps/find/authorsview.
authors/authorartworkinstructions or contact the Editorial Office 
(jmd@asip.org).  
Figure Legends. Figure legends should be submitted as part of the 
manuscript (separate from the figure files) and should describe any 
staining method and degree of magnification. If the exact scale is 
critical, scale bars should be used on the photograph and specified in 
the legend. Figure legends should adequately describe all descriptors: 
arrows, arrowheads, scale bars, insets, asterisks, boxes/circles/etc in 
line graphs, and any other notations. Descriptive text, rather than 
graphics inserted into the text, should be used when possible (eg, 
closed circles, open boxes, hatched bars, etc); alternatively, a legend 
key should be included in the figure. Statistical significance (eg, P 
values) should be clearly defined by asterisks (*, **, ***) or by other 
sequential symbols: *, †, ‡, §, ¶,Œ; these may be doubled up if needed. 
. P values should be labeled by symbol in the image, with definitions 
appearing only in the legend. Labeling of data as not significant (NS) is 
unnecessary. All abbreviations should also be defined.  
Data Supplements and Non-Traditional Media. Figures and tables that 
are critical to the evaluation and understanding of the research 
presented, but which cannot be accommodated via the print medium 
(eg, video), will be considered part of the manuscript submission and 
will be published on the Journal website if the manuscript is accepted. 
Supplemental figures (PDF, TIFF, or EPS), tables (MS Word or Excel), 
and legends (MS Word) should be prepared as above. Supplemental 
material published on the Journal website is subject to the same 
copyright as applies to the printed article. Online data will remain 
associated with its article and is not subject to any modifications or 
updates after publication. Authors of accepted manuscripts will be 
charged US$65 per supplemental data file to be published on the 
Journal website (up to 1MB; files over 1MB will be charged an 
additional US$65 per megabyte). Authors are therefore encouraged to 
minimize the size of their supplemental data files. 
Complex data sets such as microarray data and gene sequences should 
be deposited in a reliable public archive. Microarray repositories 
should comply with the Minimum Information About a Microarray 
Experiment (MIAME) guidelines (http://www.mged.org/Workgroups/
MIAME/miame_1.1.html). Examples include Gene Expression 
Omnibus (http://www.ncbi.nlm.nih.gov/geo/) and Array Express 
(http://www.ebi.ac.uk/arrayexpress/). Tissue microarray data exchange 
specifications can be found at http://www.biomedcentral.com/1472-
6947/3/5. Otherwise, the data may be published as supplemental data 
on the Journal=s website (http://jmd.amjpathol.org). 
Other materials that are not required to understand and evaluate the 
article may be stored on an institutional website and referenced as a 
URL within the manuscript text. In this case, the authors must assume 
responsibility for maintaining a live, unrestricted link to the material 
from the URL published within the article, in perpetuity. Failure to 
maintain a live, unrestricted link may result in retraction of the article 
by the Editors. Material that has been published previously (print or 
online) is not acceptable for posting as supplementary data. Instead, the 
appropriate reference(s) to the original publication should be made in 
the text and references.  
The Editors will make the final determination as to whether a given 
data set is essential to the manuscript and whether they will require 
publication of the material on the Journal website. Failure to relinquish 
required materials for online publication can result in the reversal of a 
manuscript’s acceptance.  
Copyright. Copyright of published manuscripts is held by the 
Association for Molecular Pathology and the American Society for 
Investigative Pathology, which must receive the assignment of 
copyright from the authors of accepted manuscripts. For US 
government employees, the above assignment applies only to the 
extent allowed by law. See http://www.asip.org/pubs/jmdrights.pdf  
for details. 
Publishing in The Journal of Molecular Diagnostics automatically 
places authors in compliance with the NIH Public Access Policy (see 
http://publicaccess. nih.gov/submit_process.htm, Submission Method 
A). Any article noted as being funded by NIH, HHMI, Wellcome 
Trust, or MRC is deposited in PubMed Central (PMC), to be made 
available to the public twelve months after final print publication 
(unless the funding agency stipulates a sooner release date, such as six 
months). Authors therefore should NOT complete a separate deposit of 
their material but will be contacted by PubMed Central for grant 
verification once the article has been received by the PMC article 
system. For information on how to cite articles in NIH grant 
applications, please visit http://www.asip.org/pubs/AuthorNotice.cfm. 
Contact healthpermissions@elsevier.com regarding permission to 
deposit manuscripts in other government-sponsored repositories in 
cases where The Journal of Molecular Diagnostics does not have a 
system in place to automatically deposit materials on behalf of their 
authors. Deposit of accepted or published manuscripts in any non-JMD 
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repository without prior permission by the Journal is a violation of 
copyright. 
Embargo Policy. All information regarding the content of submitted or 
accepted manuscripts is strictly confidential. Information contained in 
or about accepted articles cannot appear in print, audio, video, or 
digital form or be released by the news media until the Journal 
embargo date has passed, not to exceed the publication date of the 
article. For detailed information on embargo release dates or for news 
media requests for preprint copies of specific articles, contact 
asipproduction@elsevier.com. 
Financial Disclosure and Conflicts of Interest. All authors must 
disclose any current or former relationships (eg, employment, 
consultancies, board membership, stock ownership, funding, honoraria, 
expert testimony, patents or royalties, travel reimbursements, industry-
supplied free reagents, etc) with any organization or entity having a 
direct financial or personal interest in the subject matter or materials 
discussed in the article. Authors should err on the side of full disclosure 
and should contact the Editorial Office if they have questions or 
concerns. This information should be provided at the time of 
submission and reiterated as part of copyright assignment. Failure to do 
so may result in manuscript rejection or editorial retraction of the 
article. Further information can be found in the Journal Scientific 
Integrity Policy at http://www.journals.elsevierhealth.com/periodicals/ 
jmdi/content/integrity. Upon manuscript acceptance, all coauthors will 
be instructed to formally disclose all potential conflicts. 
Publication Charges 
Figure and Table Charges: Authors will be charged US$550 per color 
figure, US$50 per black & white or grayscale figure, and US$50 per 
composed table, per printed page (ie, figures or tables necessitating 
more than one printed page will incur an additional charge). 
Corresponding authors of published manuscripts who are current, dues-
paying regular members of ASIP at the time of submission will receive 
one free color figure as a benefit of membership; page charges will not 
be waived for ASIP members.  
Page Charges: Authors will be charged US$65 per printed page. 
Manuscripts arising from research in developing countries may be 
eligible for waiver of publication charges only if all authors are located 
in a qualifying country (for a list of eligible countries, see Group A and 
Group B countries at http://www.who.int/hinari/ eligibility/en). 
Otherwise, page charges will not be waived, except for solicited 
editorials. 
Approval of Fees and Invoicing: A summary of publication charges 
(figures, tables, and supplemental data) will be presented to the 
corresponding author of accepted manuscripts for approval prior to 
publication; final page charges cannot be determined until final 
publication. Color figure charges will not be waived, but color figures 
may be published in black and white, pending editorial approval. 
Requests for black and white figure publication must be made prior to 
execution of the publication charge approval form to avoid color 
charges. A final invoice will be presented immediately after 
publication; full payment is expected at that time. Failure to pay 
publication charges may result in the authors’ inability to publish 
future articles in The Journal of Molecular Diagnostics. 
Open Choice. In addition to publication charges outlined above, 
authors may elect to participate in the Journal’s Open Choice program. 
Articles published under Open Choice will become immediately 
accessible on the Journal website upon publication, without the twelve-
month subscriber-only access delay. Authors wishing to participate 
should contact the Editorial Office following manuscript acceptance. 
All copyright restrictions regarding reuse still apply. Cost to participate 
is US$1500, which must be received before article restriction is lifted.  
Reprints. Reprints should be ordered when page proofs are returned; 
an order form is included with the proofs. Late reprint orders may 
result in additional fees. There is no extra charge for color reprints. 
Author reprints will be supplied in CMYK color mode because it is a 
printed medium, but electronic reprints will be supplied in RGB color 
mode for visualization on screen. Each author will receive one 
complimentary electronic (secure PDF) reprints for distribution at their 
discretion. Additional electronic reprints can be ordered at the time 
page proofs are returned or at a later date. No hardcopy complimentary 
reprints are provided. 
Proofs. The corresponding author will be contacted by email once 
proofs are ready and will be directed to download electronic proofs 
from a secure website. Electronic page proofs will be provided in RGB, 
thus reflecting the online quality. Image files will be converted to 
CMYK for the printed journal; all images published online will be in 
RGB. Full instructions on completing proof corrections will be 
provided with the downloaded proof. The author should check the 
proofs carefully, mark any printer’s errors, and answer queries as 
requested. Author changes should be kept to a minimum. Proof 
corrections and replacement figures (if any) must be returned within 24 
hours to avoid any delay in publication.  
Cover Figure. The cover figure is selected by the Editors from 
illustrations appearing in the issue. Authors are encouraged to suggest 
a figure for consideration, or include an additional cover figure 
submission along with their manuscript submission. Cover figures are 
published at no charge; cover reprints are available as cover stock 
reprints or posters (no complimentary cover reprints are provided). 
Editorial Communications. All correspondence concerning editorial 
matters should be addressed to the Editor-in-Chief at The Journal of 
Molecular Diagnostics, 9650 Rockville Pike, Bethesda, Maryland, 
USA 20814-3993, faxed to 301-634-7961, or emailed to 
jmd@asip.org. Appeals (rebuttals) to editorial decisions must be 
submitted within 60 days to be considered. Letters to the Editor will 
be printed at the Editors’ discretion in the Correspondence section.  
Corrections are published upon request and after editorial review. 
Retractions are published upon request of authors or their institutions 
and may also be published by the Journal following a determination of 
scientific misconduct. Notes of Concern are published in response to 
editorial concerns relating to scientific or publishing misconduct by 
authors or reviewers or to alert the scientific community of an ongoing 
investigation.    
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